Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck KGaA
Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A clinical study in prostate cancer using a monoclonal antibody
The primary objective of the trial is to evaluate the clinical anti-tumor acitivity of EMD 525797 administered as 1-hour intravenous (i.v.) infusion every 3 weeks in terms of progression free surv...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
EMD Pharmaceuticals, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany)
Update Il y a 4 ans
Randomized, phase II, open-label controlled study of two different doses and schedules of EMD 72000 (matuzumab) in combination with pemetrexed, or pemetrexed alone, as second-line treatment in subjects with Stage IIIB/IV non-small cell lung cancer and progressive disease on or after first-line treatment with a platinum analogue in combination with either taxanes, gemcitabine or vinorelbine
To determine the tumor response rate (as assessed by the Independent Review Committee [IRC]) of 2 different regimens of matuzumab in combination with pemetrexed in comparison to pemetrexed alone in su...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A study to investigate the safety and effectiveness of different doses of a new drug (sprifermin- also called AS902330) in patients with osteoarthritis of the knee
To evaluate structural changes in cartilage thickness in the total femorotibial joint of the target knee in terms of imaging by magnetic resonance imaging (MRI)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Merck KGaA
Update Il y a 4 ans
Étude MS200647_0037 : étude de phase 2, évaluant l’efficacité du bintrafusp alfa par rapport au pembrolizumab, comme traitement de première ligne, chez des patients ayant un cancer du poumon non à petites cellules de stade avancé exprimant PD-L1.
Le cancer du poumon non à petites cellules est le plus fréquent, il représente 85-90 % de l'ensemble des cancers du poumon. Il prend habituellement naissance dans les cellules glandulaires situées dan...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment
Determine the recommended phase II dose (RP2D) of MSC2156119J. Evaluate efficacy of MSC2156119J in subjects with MET+ advanced HCC pretreated with sorafenib and Child Pugh class A liver function.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator
The primary objective of this trial is to demonstrate the effect of ONO 4641 versus interferon (IFN) ? 1a (Avonex) 30 µg on the proportion of subjects, with relapsing-remitting multiple sclerosis (RRM...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Merck KGaA
Update Il y a 4 ans
Étude COMBO : étude de phase 1b évaluant la sécurité, la tolérance et la pharmacocinétique de l’avélumab en association avec du NHS-IL12 chez des patients ayant des tumeurs solides localement avancées non résécables ou métastatiques.
Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquentes puisqu’elles représentent 90 % des cancers humains. On distingue 2 ...
Country
France
organs
Poumon, type non à petites cellules
,
Appareil urinaire - autres
,
Côlon ou Rectum (colorectal)
,
Rein
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merck Serono International, An affiliate of Merck KGaA, Darmstadt, Germany
Update Il y a 4 ans
A Phase II/III, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of atacicept in combination with corticosteroids and sequential therapy with cyclophosphamide and azathioprine in subjects with lupus nephritis
PRIMARY The primary objective of this trial is to evaluate the efficacy of atacicept compared to placebo in subjects with active LN who are receiving corticosteroids and sequential therapy with cyclop...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone
Overall survival time
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Open-label, single-arm, multicenter phase II study of matuzumab in combination with irinotecan background chemotherapy in subjects with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer that developed progressive disease while on therapy or within 4 weeks after termination of an irinotecan based regimen
To determine the response rate of matuzumab in combination with irinotecan background chemotherapy for EGFR-expressing metastatic colorectal cancer which developed PD while on therapy or within 4 week...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
Next